Government to Expand Production of Alzheimer’s Drug Lecanemab

By the Editorial Team · Thursday, September 17, 2026

The UK government has pledged £48 million to expand a manufacturing facility for lecanemab, an Alzheimer’s drug, to increase its global supply. This investment aims to establish the UK as a key producer internationally, even though lecanemab is not yet available through the NHS.

The United Kingdom government has committed to funding a £48 million expansion of a manufacturing facility that produces lecanemab, an Alzheimer’s disease treatment, to enable increased global distribution. The investment will boost the site’s capacity to supply the drug internationally, despite lecanemab not currently being available on the National Health Service (NHS).

Lecanemab has been demonstrated to slow functional decline in Alzheimer’s patients by approximately one-third, offering a significant advancement in treatment options. While the drug is gaining international attention for its efficacy, local access through the NHS has yet to materialize.

The planned expansion reflects the government’s intention to position Britain as a key supplier of this medication to markets abroad. Details on the specific timeline of the project or the reasons for the drug’s absence from NHS formularies have not been disclosed.

Industry experts expect that increasing production capabilities may help reduce costs and improve availability worldwide, although questions remain regarding domestic access for patients facing Alzheimer’s disease in the UK.

This move comes amid ongoing debates over the cost-effectiveness and approval processes of new Alzheimer’s treatments within national healthcare systems, highlighting the complex balance between supporting global pharmaceutical innovation and addressing local patient needs.

This article was reported by synthesizing coverage from multiple independent news outlets to present a balanced, unbiased account. Read about our editorial standards. Spotted an error? Let us know.